Establishment Labs Holdings

Surgeon Adoption And Patient Demand Will Expand Markets

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

28 May 25

Updated

05 Dec 25

Views

47

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

66.0%

7D

4.4%

Loading

1Y

66.0%

7D

4.4%

You can edit this narrative until Dec 6 11:10 PM. Then, changes will post as Updates.

Author's Valuation

US$74.220.1% undervalued

AnalystConsensusTarget Fair Value

Shared on 05 Dec 25

Fair value Increased 4.05%

ESTA: Positive EBITDA And U S Expansion Will Support Balanced Outlook

Analysts have lifted their price target on Establishment Labs Holdings, increasing fair value estimates to about $74 from roughly $71, supported by stronger than expected Q3 results, the company’s first positive EBITDA, and raised 2025 revenue expectations. Analyst Commentary Recent research notes highlight a generally constructive stance on Establishment Labs Holdings, with multiple firms lifting price targets following the latest Q3 results and updated 2025 guidance.

Shared on 21 Nov 25

Fair value Increased 15%

ESTA: Continued U S Sales Gains And Improved Margins Will Support Balanced Outlook

Analysts have raised their price target for Establishment Labs Holdings from $62.22 to $71.33 per share, reflecting continued outperformance in Q3 results, improving profit margins, and increased confidence in future revenue growth. Analyst Commentary Analysts have responded to Establishment Labs Holdings' recent performance with revised outlooks, highlighting both areas of strength and potential challenges for the company.

Shared on 07 Nov 25

Fair value Increased 12%

ESTA: Positive Earnings And U S Market Expansion Will Drive Balanced Outlook

The analyst price target for Establishment Labs Holdings has increased from $55.44 to $62.22 per share. Analysts cite strong Q3 results, improved profit margins, and raised revenue guidance as key drivers of this upward revision.

AnalystConsensusTarget Fair Value

US$74.22

0.1% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

22.84%

Medical Equipment revenue growth rate

7.79%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

12.87%

Calculation

US$39.59m

Earnings '28

x

78.24x

PE Ratio '28

=

US$3.10b

Market Cap '28

US$3.10b

Market Cap '28

/

29.70m

No. shares '28

=

US$104.29

Share Price '28

US$104.29 Share Price '28

Discounted to 2025 @ 12.90% p.a.

=

US$72.46

Fair Value '25